Assessment of variability and normalization methods using the plasma 7K SomaScan® Assay v4.1

Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1

The 7K SomaScan Assay v4.1 is capable of measuring 7,288 human proteins. In this webinar, the speakers present the largest technical assessment of this platform to date based on a study of 2,050 samples across 22 plates. Included in the study design were inter-plate technical duplicates from 102 human subjects, which allowed them to characterize different normalization procedures, evaluate assay variability by multiple analytical approaches, present signal-over-background metrics, and discuss potential specificity issues.

By providing detailed performance assessments on this wide range of technical aspects, the presenters aim for this work to serve as a valuable resource for the growing community of SomaScan users.

Topics covered:

  • A comparative analysis of different normalization strategies
  • An analysis of performance across 7,288 SOMAmers® targeting human proteins
  • A discussion of sensitivity and specificity of the assay

Profile image of Julian Candia, PhD

Julián Candia, PhD

Staff Scientist
Longitudinal Studies Section
Translational Gerontology Branch
National Institute on Aging
National Institutes of Health

Image of Dr Keenan Walker

Keenan Walker, PhD

Investigator, National Institute on Aging Intramural Research Program
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND) unit

Assessment of variability and normalization methods using the plasma 7K SomaScan Assay v4.1

A presentation by Julián Candia, PhD, and Keenan Walker, PhD

Share with colleagues

More webinars

WebinarMapping the human mucosal immune response to respiratory viruses

Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.

Learn more

WebinarAccelerating precision medicine of cancer with SomaScan® proteomics

Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology -- the SomaScan Platform, which measures 7,000 proteins -- to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.

Learn more

WebinarImproving clinical development productivity with high-plex proteomics

While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete. Assessment of the human proteome is thus increasingly recognized as a priority for successful and cost-effective drug development and clinical research.

Learn more